Lexatumumab

N/A

Report date: 2022/05/18 16:21:08

Base Information

Drug NameLexatumumab
Drug Alias NameAnti-TRAIL receptor-2 monoclonal antibody来沙木单抗Death receptor 5 monoclonal antibodyTRAIL-R2 human monoclonal antibodyTRAIL-R2 monoclonal antibody +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 10B agonistsApoptosis stimulants
TargetsTumor necrosis factor receptor superfamily member 10B
Therapy Area/IndicationsNeuroblastomaRhabdomyosarcomaSarcoma, Ewing +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Pharmaceutical Co LtdGlaxosmithkline PlcNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsNeuroblastomaRhabdomyosarcomaSarcoma, Ewing +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG